Skip to content

Study · In vitro (cells) · mouse · 2000

11 results

Activation of murine bone-marrow derived macrophages in vitro with Thymosin-alpha-1 to tumoricidal state: a comparative study on normal and tumour-bearing hosts.

Paul S, Sodhi A, Biswas SK

International journal of immunopathology and pharmacology1 Sept 2000Cited by 5 (Europe PMC)

PMID12657202 (opens in a new tab)PepBankPUB-12657202

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In murine bone-marrow derived macrophages, thymosin alpha‑1 activated the cells to a tumoricidal state in vitro.

    In plain wordsIn mouse immune cells in the lab, thymosin alpha‑1 made the cells able to kill tumor cells.

    Outcome
    IncreaseMacrophage tumoricidal activity
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The present investigation establishes the ability of Thymosin alpha l (T alpha l) to activate murine bone-marrow derived macrophages (BMDMs) in vitro to tumoricidal state with concomitant release of NO, TNFalpha and IL-1.
  2. 02LabIn vitro (cells)Activity measurement

    In murine bone-marrow derived macrophages, thymosin alpha‑1 was linked to release of nitric oxide in vitro.

    In plain wordsIn mouse immune cells in the lab, thymosin alpha‑1 treatment came with release of nitric oxide.

    Outcome
    IncreaseNitric oxide release
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The present investigation establishes the ability of Thymosin alpha l (T alpha l) to activate murine bone-marrow derived macrophages (BMDMs) in vitro to tumoricidal state with concomitant release of NO, TNFalpha and IL-1.
  3. 03LabIn vitro (cells)Activity measurement

    In murine bone-marrow derived macrophages, thymosin alpha‑1 was linked to release of TNF-alpha in vitro.

    In plain wordsIn mouse immune cells in the lab, thymosin alpha‑1 treatment came with release of TNF-alpha.

    Outcome
    IncreaseTNF-alpha release
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The present investigation establishes the ability of Thymosin alpha l (T alpha l) to activate murine bone-marrow derived macrophages (BMDMs) in vitro to tumoricidal state with concomitant release of NO, TNFalpha and IL-1.
  4. 04LabIn vitro (cells)Activity measurement

    In murine bone-marrow derived macrophages, thymosin alpha‑1 was linked to release of IL-1 in vitro.

    In plain wordsIn mouse immune cells in the lab, thymosin alpha‑1 treatment came with release of IL-1.

    Outcome
    IncreaseIL-1 release
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The present investigation establishes the ability of Thymosin alpha l (T alpha l) to activate murine bone-marrow derived macrophages (BMDMs) in vitro to tumoricidal state with concomitant release of NO, TNFalpha and IL-1.
  5. 05LabIn vitro (cells)Efficacy outcome

    In murine bone-marrow derived macrophages, thymosin alpha‑1 induced cytotoxicity that depended on dose and time.

    In plain wordsIn mouse immune cells in the lab, thymosin alpha‑1 killed tumor cells more with higher doses and longer exposure.

    Outcome
    IncreaseCytotoxicity dose and time dependence
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The T alpha l-induced cytotoxicity and the secretion of soluble lytic factors were both dose- and time dependent.
  6. 06LabIn vitro (cells)Activity measurement

    In murine bone-marrow derived macrophages, thymosin alpha‑1 induced secretion of soluble lytic factors that depended on dose and time.

    In plain wordsIn mouse immune cells in the lab, thymosin alpha‑1 raised secretion of cell-killing factors with dose and time.

    Outcome
    IncreaseSoluble lytic factor secretion dose and time dependence
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The T alpha l-induced cytotoxicity and the secretion of soluble lytic factors were both dose- and time dependent.
  7. 07LabIn vitro (cells)Efficacy outcome

    After thymosin alpha‑1 activation, macrophages from Dalton's Lymphoma-bearing mice had lower cytolytic activity against DL tumour target cells than macrophages from normal mice.

    In plain wordsAfter thymosin alpha‑1 treatment, macrophages from tumor-bearing mice killed tumor cells less well than macrophages from normal mice.

    Outcome
    DecreaseCytolytic activity in Dalton's Lymphoma-bearing mouse macrophages
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Comparator
    Macrophages from normal mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    BMDMs cultured from the Dalton's Lymphoma bearing mice (DL-BMDMs) exhibited reduced cytolytic activity towards DL-tumour target cells on activation with T alpha l as compared to the BMDMs obtained from normal mice (N-BMDMs).
  8. 08LabIn vitro (cells)Activity measurement

    With thymosin alpha‑1, macrophages from Dalton's Lymphoma-bearing mice released more TNF-alpha than macrophages from normal mice.

    In plain wordsWith thymosin alpha‑1, macrophages from tumor-bearing mice released more TNF-alpha than macrophages from normal mice.

    Outcome
    IncreaseTNF-alpha release in Dalton's Lymphoma-bearing mouse macrophages
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Comparator
    Macrophages from normal mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The DL-BMDMs displayed enhanced TNFalpha and IL-1 release as compared to the N-BMDMs when treated with T alpha l.
  9. 09LabIn vitro (cells)Activity measurement

    With thymosin alpha‑1, macrophages from Dalton's Lymphoma-bearing mice released more IL-1 than macrophages from normal mice.

    In plain wordsWith thymosin alpha‑1, macrophages from tumor-bearing mice released more IL-1 than macrophages from normal mice.

    Outcome
    IncreaseIL-1 release in Dalton's Lymphoma-bearing mouse macrophages
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Comparator
    Macrophages from normal mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The DL-BMDMs displayed enhanced TNFalpha and IL-1 release as compared to the N-BMDMs when treated with T alpha l.
  10. 10LabIn vitro (cells)Activity measurement

    With thymosin alpha‑1, nitric oxide production was lower in macrophages from Dalton's Lymphoma-bearing mice than in macrophages from normal mice.

    In plain wordsWith thymosin alpha‑1, macrophages from tumor-bearing mice made less nitric oxide than macrophages from normal mice.

    Outcome
    DecreaseNitric oxide production in Dalton's Lymphoma-bearing mouse macrophages
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Comparator
    Macrophages from normal mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the other hand, it is observed that the production of NO and the expression of iNOS was higher in the N-BMDMs as compared to the DL-BMDMs on treatment with T alpha l.
  11. 11LabIn vitro (cells)Activity measurement

    With thymosin alpha‑1, iNOS expression was lower in macrophages from Dalton's Lymphoma-bearing mice than in macrophages from normal mice.

    In plain wordsWith thymosin alpha‑1, macrophages from tumor-bearing mice showed less iNOS than macrophages from normal mice.

    Outcome
    DecreaseiNOS expression in Dalton's Lymphoma-bearing mouse macrophages
    Study

    mousen: not reported in source

    bone-marrow derived macrophages
    Comparator
    Macrophages from normal mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the other hand, it is observed that the production of NO and the expression of iNOS was higher in the N-BMDMs as compared to the DL-BMDMs on treatment with T alpha l.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.